We continue to monitor the medical literature for developments related to gadolinium retention in connection with our investigation of cases of Gadolinium Deposition Disease (GDD) in patients who received injections of gadolinium based contrast agents for their MRI, MRA, or CT scan procedure. Presented below is a collection of medical articles … [Read more...]
Gadolinium Deposition Disease Explained: How It Is Diagnosed, And More
A person who received an injection of a gadolinium-based contrast agent (GBCA) may develop some medical conditions following their MRI or MRA procedure which could be symptoms of gadolinium deposition disease. These various gadolinium-related symptoms include: Persistent headache; “Brain fog”; Skin that appears spongy or rubbery, … [Read more...]
Gadolinium-Based Contrast Agents: Timeline of FDA Regulatory Actions
In my last article on Gadolinium based contrast agents (GBCAs), I discussed some of the side effects of these injections, which are administered to patients during a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA). While GBCAs have started to draw attention in the pharmaceutical products liability legal realm, they have … [Read more...]
Gadolinium Deposition Disease can Result from use of Contrast Agents During MRI & MRA Procedures
What are Gadolinium-Based Contrast Agents (GBCAs)? GBCAs are substances that are injected into patients during Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) in order to produce clearer radiology images. Here is a list of GBCAs that are currently approved by the FDA: Ablavar Dotarem Eovist Gadavist … [Read more...]